Share This Page

Support & Insight for the Autumn of Life

Eye Test for Alzheimer’s: Cognoptix Promises Cheaper, Faster, Better

Human eye

VIDEO+ARTICLE

Cognoptix announced strong results in a clinical trial of its SAPPHIRE II eye test. It successfully identified Alzheimer’s via the human eye’s beta-amyloid signature. See how Cognoptix will check if you are clear of Alzheimer’s, right in your doctor’s office.


Cognoptix published strong results of a multi-site clinical trial of its SAPPHIRE II eye test in the peer-reviewed Journal of Alzheimer’s Disease & Other Dementias® (AJA).

“Our vision is to change the course of Alzheimer’s disease by enabling early diagnosis at the point of care,” said Cognoptix President and CEO Paul Hartung.

“We have made great progress, ” Hartung added, “in developing an early-stage, non-invasive diagnostic test for AD designed to allow treatment to start before significant neuronal loss and irreversible brain damage occur.”

By detecting a specific fluorescent signature of ligand-marked A-beta in the supranucleus region of the human lens, SAPPHIRE II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable AD from a group of 20 age-matched healthy volunteers. In addition, the SAPPHIRE II test showed excellent correlation to PET (positron emission tomography) amyloid brain imaging.

“The easy-to-use SAPPHIRE eye test has demonstrated the clinical potential to remake the paradigm for the way in which Alzheimer’s Disease is currently diagnosed and managed,” said Carl Sadowsky, MD, FAAN, Medical Director, Premiere Research Institute, West Palm Beach, Fla., and a principal investigator in the clinical trial of the SAPPHIRE eye test.

“We are delighted with the results of this feasibility study, which demonstrates the safety and effectiveness of our product, and are honored to have our work recognized in a well-respected, peer-reviewed journal,” said Paul Hartung, President and CEO of Cognoptix. “Our vision is to help change the course of Alzheimer’s disease by enabling early diagnosis at point-of-care.”


MORE INFORMATION:

About Cognoptix
Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease (AD). Its investors include Inventages Venture Capital, one of the world’s largest life sciences-, nutrition- and wellness-focused venture capital firms; Launchpad Venture Group, a Boston-based angel investment firm that provides funding to early-stage companies; and Maine Angels, accredited private equity investors in promising New England entrepreneurs and companies.

About AJA
American Journal of Alzheimer’s Disease & Other Dementias® (AJA) is for professionals on the frontlines of Alzheimer’s care, dementia, and clinical depression–especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).

Email me when people comment
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Music/Movies

“Alive Inside”

The help-dementia-with-music movie, “Alive Inside”, tells the story of social worker Dan Cohen’s crusade to help Alzheimer’s patients reclaim their most precious musical memories. Watch Bill Newcott interview the makers of the film.

Read More »
Drugs

ARIA in Lacanemab, Donanemab and Aduhelm

A neuroradiologist at the Mayo Clinic in Jacksonville, FL warns that increased use of monoclonal antibody treatment for Alzheimer’s has also led to the discovery of amyloid-related imaging abnormalities — ARIA. Find out more.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter